10 Best Growth Stocks to Buy for the Next Decade

Page 1 of 3

On November 5, the S&P 500 fell 4.36%, its worst day since the April 2025 tariff crash, with roughly $3 trillion in value wiped off S&P 500 companies. The Nasdaq Composite dropped 5.52% to slip into a correction, and chip stocks took the hardest hit, with the Philadelphia Semiconductor Index falling about 12%, its worst day since 2020. The slide followed a rough October, when the technology sector of the S&P 500 lost 6.8%, its biggest monthly drop since March 2025, while defensive groups such as consumer staples had a record month. Growth stocks tend to feel these swings first, because their prices rest on the promise of faster sales and earnings than the rest of the market.

Investors Question the Cost of AI

The worry behind the selling is money. Investors are asking how companies will pay for their enormous artificial intelligence budgets and whether the returns will justify them. The midterm election results added a second concern, as investors began questioning whether the pace of data center construction could slow if new rules follow, which would weigh on AI spending. Our ranking of semiconductor stocks to hold for the next decade covers more of the group that took the sharpest hit.

Why a Ten-Year View Looks Past One Bad Month

A growth stock is a share in a company expected to grow its sales and earnings faster than the market average. These companies usually reinvest profits instead of paying dividends, so shareholders are rewarded through a rising share price, which is why the shares often carry high price-to-earnings ratios. A high multiple is not automatically expensive if the growth keeps coming, but it leaves little room for disappointment, and a stock priced for strong growth can fall sharply when the numbers fall short. Time helps in the other direction, because returns that stay invested earn returns of their own, a snowball effect that builds the longer the money is left alone.

The economy is adding another variable. October’s jobs report showed payrolls up 165,000, far above the 65,000 economists expected, and traders now put the odds of a Federal Reserve rate hike in December above 75%. Edward Jones senior global strategist Angelo Kourkafas called it a “blowout jobs report.” A strong economy is good for business, but higher interest rates make far-off earnings worth less today, which tends to weigh most on growth stocks. For readers hunting for bargains after the pullback, our list of undervalued growth stocks is a place to start. For long-term holders, the more useful question is not what the market does next month but which companies can keep compounding through several more months like this one.

10 Best Growth Stocks to Buy for the Next Decade

Our Methodology

To compile this list, we searched for the best stocks to hold for the next 10 years across investor forums, social media, and financial websites, keeping only growth stocks mentioned by at least three different sources. From those, we picked the 10 with the largest market caps and ranked them in ascending order of market cap. We also list hedge fund holders as of Q2 2026.

Note: All data was sourced on November 9, 2026.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

10 Best Growth Stocks to Buy for the Next Decade

10. Micron Technology (NASDAQ:MU)

Number of Hedge Fund Holders: 184

Market Cap: $825.89 billion

Gavin Baker, who runs Atreides Management, has been one of the most outspoken voices on memory chips, arguing that the shortage will last and that Micron looks inexpensive for what it earns. Philippe Laffont’s Coatue Management backed that view with money, adding nearly three million shares in a single quarter, and David Tepper’s Appaloosa tripled its own stake late last year before trimming some of it.

Micron’s own results give them something to point to. Revenue in the fiscal fourth quarter reached $54.23 billion, up 379% from a year earlier, and the full year came in at $133.19 billion, with data center revenue up fourfold. Gross margin and earnings per share also set records.

Chief Executive Officer Sanjay Mehrotra said the company has agreements covering the vast majority of its calendar 2027 high-bandwidth memory supply, at significantly higher prices than a year earlier, and that he expects an even stronger fiscal 2027. That is the part that turns a strong quarter into a decade-long argument: customers have agreed to buy most of the high-bandwidth memory Micron plans to supply next year, before it has been made, which gives the long-term pitch a base of demand to stand on.

Read our analysis on Micron Technology (MU) here: Micron (MU) Is Trading at 5x Earnings Despite 87% Margins. What Is Wall Street Missing?

9. Eli Lilly (NYSE:LLY)

Number of Hedge Fund Holders: 152

Market Cap: $1.33 trillion

Cathie Wood’s Ark Invest bought Lilly shares this year, treating it as the GLP-1 leader with a deep pipeline in other diseases. Baron Funds, founded by Ron Baron, wrote in a shareholder letter that it sees Mounjaro, Zepbound, and the oral drug orforglipron as transformational and expects this drug class to become the standard of care for diabetic and non-diabetic obese patients alike. Ken Griffin’s Citadel also nearly quadrupled its stake in the second quarter.

The latest quarter shows how that demand is building. Revenue rose 39% to $24.4 billion, led by Mounjaro and Zepbound, and Lilly raised its 2026 revenue outlook by $5.5 billion at the midpoint. Chief Executive Officer David Ricks said the growth came from broad global consumer demand for the two drugs, the global launches of Foundayo, and expanded US coverage.

The pipeline is the other half of the pitch. Lilly reported positive Phase 3 results for retatrutide in a head-to-head trial against Ozempic in adults with type 2 diabetes, and said Phase 3 trials of another candidate are set to start. For the bulls, that steady flow of new medicines is what lets Lilly keep growing after today’s best sellers mature.

You can read our analysis on Eli Lilly (LLY) here: Eli Lilly (LLY) Grew Revenue 48% While Prices Fell, Can Volume Keep Winning?

Page 1 of 3